These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17557968)

  • 1. Targeting human epidermal growth factor receptor 2: it is time to kill kinase death human epidermal growth factor receptor 3.
    Menendez JA; Lupu R
    J Clin Oncol; 2007 Jun; 25(17):2496-8; author reply 2499. PubMed ID: 17557968
    [No Abstract]   [Full Text] [Related]  

  • 2. Gastric cancer: trastuzumab trial results spur search for other targets.
    Hede K
    J Natl Cancer Inst; 2009 Oct; 101(19):1306-7. PubMed ID: 19755679
    [No Abstract]   [Full Text] [Related]  

  • 3. Advances in HER2-positive breast cancer.
    Sledge GW
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):98-100. PubMed ID: 18347559
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on HER-kinase-directed therapy in prostate cancer.
    Gross ME; Jo S; Agus DB
    Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab--mechanism of action and use.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    N Engl J Med; 2007 Oct; 357(16):1664; author reply 1665-6. PubMed ID: 17942884
    [No Abstract]   [Full Text] [Related]  

  • 6. [Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
    Nielsen DL; Andersson M
    Ugeskr Laeger; 2007 Sep; 169(37):3085-7. PubMed ID: 17877954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Breast cancer and Her-2].
    Hatake K
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():87-94. PubMed ID: 17682144
    [No Abstract]   [Full Text] [Related]  

  • 8. [Epidermal growth factor receptor family and targeted anticancer therapy].
    Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):577-9. PubMed ID: 17134561
    [No Abstract]   [Full Text] [Related]  

  • 9. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
    Dalmases A; Rojo F; Rovira A; Albanell J
    Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
    [No Abstract]   [Full Text] [Related]  

  • 10. [Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
    Magné N; Milano G
    Bull Cancer; 2004 Dec; 91 Suppl 4():S257-60. PubMed ID: 15899618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the epidermal growth factor receptor in colorectal carcinoma.
    Kurtin SE
    Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer.
    Krawczyk P; Chocholska S; Milanowski J
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):113-7. PubMed ID: 15314969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lapatinib moves forward in inflammatory and early HER2-positive breast cancer trials.
    Tuma RS
    J Natl Cancer Inst; 2007 Mar; 99(5):348-9. PubMed ID: 17341725
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
    Meric-Bernstam F; Hung MC
    Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
    Morse L
    ONS News; 2006; 21(8 Suppl):59-60. PubMed ID: 16925155
    [No Abstract]   [Full Text] [Related]  

  • 16. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R; O'Regan RM
    Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth factors and their receptors: new targets for prostate cancer therapy.
    Barton J; Blackledge G; Wakeling A
    Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
    Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
    Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
    Fartoux L; Desbois-Mouthon C; Poupon R; Rosmorduc O
    Gastroenterol Clin Biol; 2006 Oct; 30(10):1133-5. PubMed ID: 17075466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.